rs7152376 — NFKBIA

NFKBIA rs7152376 — An NF-κB Brake Variant That Forecasts Joint Involvement in Psoriasis

Psoriasis is not a single disease — it is a spectrum. About 2-3% of people develop psoriasis at some point in their lives, and in roughly 25-30% of them, the inflammation extends beyond the skin to attack the joints, a condition called psoriatic arthritis¹¹ psoriatic arthritis
A chronic inflammatory arthritis affecting peripheral joints, the spine, entheses (tendon/ligament insertions), and nails. Untreated PsA causes irreversible joint erosion and ankylosis within 2 years in a significant fraction of patients (PsA). Identifying which psoriasis patients are heading toward joint disease — ideally before the first erosion appears on X-ray — is one of the central unmet needs in dermatology and rheumatology. rs7152376, a regulatory variant near the NFKBIA gene, is one of the clearest genetic markers currently known for that distinction.

The Mechanism

NFKBIA encodes IκB-alpha²² IκB-alpha
IκB-alpha (Inhibitor of kappa B alpha) is the primary cytoplasmic brake on NF-κB. It physically binds the NF-κB p65/p50 dimer and sequesters it in the cytoplasm. Pro-inflammatory signals (TNF, IL-1, TLR ligands) trigger IκB-alpha phosphorylation and proteasomal degradation, releasing NF-κB to translocate to the nucleus and activate cytokine gene transcription. Once NF-κB has driven its target genes, a feedback mechanism induces fresh NFKBIA transcription to reset the system. Variants impairing this feedback allow NF-κB to remain constitutively active in inflamed tissue, the principal cytoplasmic inhibitor of NF-κB signaling. NFKBIA sits on the minus strand of chromosome 14, with rs7152376 located approximately 17.7 kb upstream in genomic coordinates — a position that corresponds to the 5' regulatory region of the gene in the direction of NFKBIA transcription. Though not within the coding sequence, the variant lies in a region consistent with enhancer or chromatin-accessibility regulation of NFKBIA expression.

Reduced IκB-alpha expression or function allows NF-κB dimers to persist in the nucleus, sustaining transcription of TNF-alpha, IL-1beta, IL-6, IL-17, and IL-23 — the cytokines that drive both synovial hyperplasia and joint erosion in PsA. The specific consequence of C-allele carriage at rs7152376 for NFKBIA transcription has not been directly characterized in reporter assays, but a 2025 single-cell RNA sequencing study³³ 2025 single-cell RNA sequencing study
Garrido et al. Single-cell RNA sequencing of circulating immune cells supports inhibition of TNFAIP3 and NFKBIA translation as psoriatic arthritis biomarkers. Frontiers in Immunology 2025 provides a mechanistic clue: NFKBIA mRNA is paradoxically overexpressed in PsA immune cells compared to cutaneous-only psoriasis, yet IκBα protein is reduced in PsA CD8+ T cells — suggesting that translational suppression, rather than transcriptional silencing, is the operative mechanism. The rs7152376 C allele may tag a haplotype that contributes to this translational inefficiency in synovial immune compartments.

The Evidence

The primary association evidence comes from a Spanish case-control study⁴⁴ Spanish case-control study
Coto-Segura P et al. Gene Variant in the NF-κB Pathway Inhibitor NFKBIA Distinguishes Patients with Psoriatic Arthritis within the Spectrum of Psoriatic Disease. Biomed Res Int 2019 enrolling 690 psoriatic disease patients and 550 healthy controls from a Northern Spanish cohort. The rare C allele of rs7152376 was significantly enriched in PsA patients compared to both healthy controls (OR=2.03, 95% CI 1.3-3.1, p<0.01) and compared to pure cutaneous psoriasis patients (OR=3.2, 95% CI 2.1-5.1, p<0.001). The 3.2-fold odds ratio for PsA versus cutaneous psoriasis is the more clinically informative figure — it is not simply that C-allele carriers are more likely to have psoriasis in general, but specifically that among people with psoriasis, C-allele carriers are far more likely to develop joint involvement.

This finding is consistent with the broader NFKBIA locus biology established by the Stuart et al. GWAS⁵⁵ Stuart et al. GWAS
Stuart PE et al. Genome-wide Association Analysis of Psoriatic Arthritis and Cutaneous Psoriasis Reveals Differences in Their Genetic Architecture. Am J Hum Genet 2015 of 3,061 PsA patients, 3,110 cutaneous psoriasis patients, and 13,670 controls in European ancestry, which confirmed NFKBIA as achieving genome-wide significance independently for both PsA and PsC, with the two subtypes showing partially distinct genetic architecture. NFKBIA is not merely a general psoriasis susceptibility gene — it is a locus where different regulatory variants specifically determine the trajectory toward joint versus skin-limited disease.

The evidence base for rs7152376 specifically is currently limited to a single European cohort study, hence the moderate evidence rating. No independent replication has been published for this exact variant, though the locus-level association is well-established. A companion variant in the same regulatory region, rs12883343, was independently identified as a PsA-specific marker in a Chinese cohort (OR=2.371 for PsA vs cutaneous psoriasis, p=4.93×10⁻¹⁰), reinforcing that NFKBIA regulatory variation tracks joint involvement across populations.

Practical Actions

For C-allele carriers with psoriasis, the actionable implication is heightened clinical vigilance for early PsA features: dactylitis⁶⁶ dactylitis
"Sausage digit" — fusiform swelling of an entire finger or toe, caused by simultaneous flexor tendon sheath inflammation and small joint synovitis. Often painless in early stages. Highly specific for PsA when it occurs in a person with psoriasis, [enthesitis | Inflammation at the site where tendons and ligaments insert into bone. The Achilles insertion, plantar fascia, and patellar tendon are the most common sites. Causes tenderness on direct pressure that most people attribute to overuse], and asymmetric peripheral joint inflammation. Early DMARD or biologic therapy started before radiographic erosion significantly improves long-term outcomes.

NF-κB pathway activity can be modulated through documented nutritional interventions: high-dose omega-3 fatty acids suppress NF-κB through GPR120 and PPARγ pathways, and vitamin D receptor activation directly induces NFKBIA transcription in immune cells. Both represent evidence-based strategies to partially compensate for impaired IκB-alpha function at this locus.

Interactions

rs7152376 and the companion NFKBIA regulatory variant rs12883343 were identified in different population cohorts (European and Chinese, respectively) and likely tag distinct but overlapping regulatory haplotypes at the same locus. They are not in perfect linkage disequilibrium and may represent partially independent functional signals within the NFKBIA regulatory region.

TNFAIP3 (A20), tagged by rs9321623 and rs5029937, is the other principal NF-κB negative regulator in psoriatic disease. A20 acts upstream of IκB-alpha by deubiquitinating TRAF6 and RIPK1, thereby limiting NF-κB activation before it reaches the IκB-alpha degradation step. Individuals carrying risk alleles at both NFKBIA and TNFAIP3 loci impair NF-κB suppression through two independent mechanisms, a combination that may define a high-risk PsA subgroup.

IL-23R (tagged by rs12044149) contributes PsA-specific risk through the Th17 axis, which is partially NF-κB-dependent. Convergence of NFKBIA regulatory impairment with IL-23R susceptibility alleles may identify patients most likely to benefit from early IL-17 or IL-23 inhibitor therapy.